MDGL
Price
$195.97
Change
+$5.03 (+2.63%)
Updated
Nov 29, 10:26 AM EST
85 days until earnings call
MRSN
Price
$1.53
Change
-$0.00 (-0.00%)
Updated
Nov 28, 6:59 PM EST
91 days until earnings call
Ad is loading...

Compare predictions MDGL vs MRSN

Header iconMDGL vs MRSN Comparison
Open Charts MDGL vs MRSNBanner chart's image
Madrigal Pharmaceuticals
Price$195.97
Change+$5.03 (+2.63%)
Volume$1.36K
CapitalizationN/A
Mersana Therapeutics
Price$1.53
Change-$0.00 (-0.00%)
Volume$350.69K
CapitalizationN/A
View a ticker or compare two or three
MDGL vs MRSN Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
MDGL vs. MRSN commentary
Nov 29, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Buy and MRSN is a Buy.

COMPARISON
Comparison
Nov 29, 2023
Stock price -- (MDGL: $190.94 vs. MRSN: $1.53)
Brand notoriety: MDGL and MRSN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 51% vs. MRSN: 32%
Market capitalization -- MDGL: $3.9B vs. MRSN: $184.49M
MDGL [@Biotechnology] is valued at $3.9B. MRSN’s [@Biotechnology] market capitalization is $184.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 0 FA rating(s) are green whileMRSN’s FA Score has 0 green FA rating(s).

  • MDGL’s FA Score: 0 green, 5 red.
  • MRSN’s FA Score: 0 green, 5 red.
According to our system of comparison, MRSN is a better buy in the long-term than MDGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 6 TA indicator(s) are bullish while MRSN’s TA Score has 6 bullish TA indicator(s).

  • MDGL’s TA Score: 6 bullish, 4 bearish.
  • MRSN’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, MRSN is a better buy in the short-term than MDGL.

Price Growth

MDGL (@Biotechnology) experienced а +1.33% price change this week, while MRSN (@Biotechnology) price change was -3.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.02%. For the same industry, the average monthly price growth was +37.81%, and the average quarterly price growth was +8.99%.

Reported Earning Dates

MDGL is expected to report earnings on Feb 22, 2024.

MRSN is expected to report earnings on Feb 28, 2024.

Industries' Descriptions

@Biotechnology (+5.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for MDGL with price predictions.
OPEN
A.I.dvisor published
a Summary for MRSN with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
MDGL($3.9B) has a higher market cap than MRSN($184M). MDGL YTD gains are higher at: -34.215 vs. MRSN (-73.891). MRSN has higher annual earnings (EBITDA): -191.71M vs. MDGL (-336.4M). MRSN (241M) and MDGL (232M) have equal amount of cash in the bank . MRSN has less debt than MDGL: MRSN (34.3M) vs MDGL (117M). MRSN has higher revenues than MDGL: MRSN (40.8M) vs MDGL (0).
MDGLMRSNMDGL / MRSN
Capitalization3.9B184M2,117%
EBITDA-336.4M-191.71M175%
Gain YTD-34.215-73.89146%
P/E RatioN/AN/A-
Revenue040.8M-
Total Cash232M241M96%
Total Debt117M34.3M341%
FUNDAMENTALS RATINGS
MDGL vs MRSN: Fundamental Ratings
MDGL
MRSN
OUTLOOK RATING
1..100
2821
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
48
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3558
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRSN's Valuation (48) in the Biotechnology industry is somewhat better than the same rating for MDGL (96) in the Pharmaceuticals Other industry. This means that MRSN’s stock grew somewhat faster than MDGL’s over the last 12 months.

MRSN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that MRSN’s stock grew similarly to MDGL’s over the last 12 months.

MRSN's SMR Rating (100) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that MRSN’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Price Growth Rating (35) in the Pharmaceuticals Other industry is in the same range as MRSN (58) in the Biotechnology industry. This means that MDGL’s stock grew similarly to MRSN’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as MRSN (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to MRSN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLMRSN
RSI
ODDS (%)
Bearish Trend 1 day ago
86%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 10 days ago
85%
Declines
ODDS (%)
Bearish Trend 21 days ago
81%
Bearish Trend 8 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 6 days ago
87%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WCMEX12.930.08
+0.62%
WCM Focused Emerging Markets Instl
PISJX14.220.03
+0.21%
Columbia Pyrford International Stock R
JHDCX15.68N/A
N/A
JPMorgan Hedged Equity 2 C
IVJIX8.78N/A
N/A
Delaware Ivy International Small Cap I
NABIX11.69-0.02
-0.17%
Neuberger Berman Abs Ret Multi-Mgr I

MRSN and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRSN has been loosely correlated with MDGL. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MRSN jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRSN
1D Price
Change %
MRSN100%
N/A
MDGL - MRSN
45%
Loosely correlated
-3.22%
ZNTL - MRSN
40%
Loosely correlated
+0.10%
AVTX - MRSN
38%
Loosely correlated
-7.12%
BHVN - MRSN
37%
Loosely correlated
-0.64%
ARRY - MRSN
36%
Loosely correlated
+1.02%
More